Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
by GlobeNewswire
Oct 09, 2024 2:17 pm
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona